TY - JOUR
T1 - Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS
T2 - Frequency, Clinical-Pathological Characteristics, and Response to Therapy
AU - Ulivi, Paola
AU - Chiadini, Elisa
AU - Dazzi, Claudio
AU - Dubini, Alessandra
AU - Costantini, Matteo
AU - Medri, Laura
AU - Puccetti, Maurizio
AU - Capelli, Laura
AU - Calistri, Daniele
AU - Verlicchi, Alberto
AU - Gamboni, Alessandro
AU - Papi, Maximilian
AU - Mariotti, Marita
AU - De Luigi, Nicoletta
AU - Scarpi, Emanuela
AU - Bravaccini, Sara
AU - Turolla, Gian Michele
AU - Amadori, Dino
AU - Crinò, Lucio
AU - Delmonte, Angelo
PY - 2015/9/4
Y1 - 2015/9/4
N2 - Background: Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation are generally considered to be mutually exclusive. However, concomitant mutations are found in a small number of patients and the effect of these on response to targeted therapy is still unknown. Patients and Methods: We considered 380 non-small-cell lung cancer (NSCLC) patients who underwent nonsequential testing for EGFR and EML4-ALK translocation. KRAS mutation analysis was also performed on 282 patients. Results: We found 1.6%, 1.1%, and 2.5% of patients who showed a double mutation comprising EGFR and EML4-ALK, EGFR and KRAS, and EML4-ALK and KRAS, respectively. Twenty-eight patients with EGFR mutation underwent first-line therapy with a tyrosine kinase receptor; a clinical benefit was observed in 81.8% of patients with EGFR mutations only and in 67% of those who also showed an EML4-ALK translocation. Twelve patients with an EML4-ALK translocation received crizotinib and 7 of these had disease progression within 3 months (2 had a concomitant KRAS mutation and 1 had a concomitant EGFR mutation). Two patients showed stable disease, 1 of whom also had a KRAS mutation. Two patients obtained a partial response and 1 had a complete response; all harbored an EML4-ALK translocation only. The median overall survival of patients who carried an EML4-ALK translocation alone or concomitant with a KRAS mutation was 57.1 (range, 10.7-not reached) and 10.7 (range, 4.6-not reached) months, respectively. Conclusion: Concomitant EGFR, EML4-ALK, or KRAS mutations can occur in NSCLC. Concomitant KRAS mutation and EML4-ALK translocation represents the most common double alteration and confers a poor prognosis.
AB - Background: Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK) translocation are generally considered to be mutually exclusive. However, concomitant mutations are found in a small number of patients and the effect of these on response to targeted therapy is still unknown. Patients and Methods: We considered 380 non-small-cell lung cancer (NSCLC) patients who underwent nonsequential testing for EGFR and EML4-ALK translocation. KRAS mutation analysis was also performed on 282 patients. Results: We found 1.6%, 1.1%, and 2.5% of patients who showed a double mutation comprising EGFR and EML4-ALK, EGFR and KRAS, and EML4-ALK and KRAS, respectively. Twenty-eight patients with EGFR mutation underwent first-line therapy with a tyrosine kinase receptor; a clinical benefit was observed in 81.8% of patients with EGFR mutations only and in 67% of those who also showed an EML4-ALK translocation. Twelve patients with an EML4-ALK translocation received crizotinib and 7 of these had disease progression within 3 months (2 had a concomitant KRAS mutation and 1 had a concomitant EGFR mutation). Two patients showed stable disease, 1 of whom also had a KRAS mutation. Two patients obtained a partial response and 1 had a complete response; all harbored an EML4-ALK translocation only. The median overall survival of patients who carried an EML4-ALK translocation alone or concomitant with a KRAS mutation was 57.1 (range, 10.7-not reached) and 10.7 (range, 4.6-not reached) months, respectively. Conclusion: Concomitant EGFR, EML4-ALK, or KRAS mutations can occur in NSCLC. Concomitant KRAS mutation and EML4-ALK translocation represents the most common double alteration and confers a poor prognosis.
KW - Crizotinib
KW - Double mutations
KW - NSCLC
KW - Prognosis
KW - Tyrosine kinase inhibitors
UR - http://www.scopus.com/inward/record.url?scp=84975743594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84975743594&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2015.11.004
DO - 10.1016/j.cllc.2015.11.004
M3 - Article
AN - SCOPUS:84975743594
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
SN - 1525-7304
ER -